Press release
SIMFO to present maintrac liquid biopsy at the BIO International Convention 2017
As one of the 15 most innovative European companies SIMFO GmbH was invited by the European Commission to the Bio International Convention (BIO) 2017 to present maintrac® liquid biopsy under the patronage of the EU. Small and medium-sized enterprises are given the opportunity to obtain comprehensive information about the US healthcare and biotech market.
At BIO, more than 16,000 biotechnology and pharmaceutical executives are expected to jointly explore new opportunities and promising partnerships. David Cameron, former Prime Minister of Great Britain, will give the opening speech.
Maintrac® is an innovative analysis platform in cancer diagnostics and therapy monitoring. Maintrac® identifies and quantifies the tumor cells (circulating tumor cells) in the blood sample of a cancer patient and analyzes the efficacy of selected drugs. In clinical trials with more than 650 patients, maintrac® has demonstrated that monitoring CETC in the adjuvant situation, during maintenance and antibody therapy in breast cancer has significant benefits. Possible relapses can be recognized at an early stage.
Further information:
www.simfo.de
www.maintrac.de
convention.bio.org
The SIMFO Specialized Immunology Research + Development GmbH, based in Bayreuth, is a medical-biologically-oriented company with a high level of competence for personalized diagnostics and cancer therapy. Particular emphasis is set up on the research and development of predictive and prognostic analysis methods for the long-term monitoring and characterization of cancer diseases. This is based on the analysis platform Maintrac®. Maintrac® provides real-time information about the tumor activity and the characteristics of the disease in order to be able to adapt the therapy within a short time frame.
SIMFO GmbH
Kurpromenade 2
95448 Bayreuth
Germany
T: 0921-730052
E: presse@simfo.de
W: www.simfo.de
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release SIMFO to present maintrac liquid biopsy at the BIO International Convention 2017 here
News-ID: 463652 • Views: …
More Releases from SIMFO Spezielle Immunologie Forschung + Entwicklung GmbH
maintrac® launches Immunotherapy PDL-1 blood test
Immunotherapy was one of the big topics at ASCO (American Society of Clinical Oncology) this year. Because of its potential, ASCO named it "The 2016 Clinical Cancer Advance of the Year". Immunotherapy is among today’s most promising approaches to improving the outcomes of patients.
Obtaining PD-L1 status previously required an invasive tissue biopsy. The highest quality liquid biopsy maintrac ® now makes an invasive procedure obsolete. A simple blood test, the…
Pretreatment testing of SIMFO anticancer drug on patient blood
Dubai / Bayreuth - At the 2nd World Conference for Drug Discovery and Therapy, Prof. Dr. Katharina Pachmann (Jena University) presented a worldwide unique approach in oncology that can detect circulating tumor cells in the blood of cancer patients.
After tumor removal, any remaining, washed out tumor cells are responsible for the development of metastases, which shorten survival time in most patients. A good, often metastasis-free prognosis of survival is achieved…
More Releases for Maintrac
Ki67 as an additional marker on circulating tumor cells
Ki67 is a nuclear protein that is associated with cell proliferation. Ki67 is present during all active phases of the growth cycle, but is absent in resting (quiescent) cells. Ki67 is identified with the IHC method. The presence of Ki67 protein on circulating tumor cells indicates the percentage of circulating tumor cells in the active growth phase of the cell cycle. Higher amounts are associated with an increased risk of…
Antithrombotic management plan for cancer patients
In Germany Thrombosis occurs 470.000 timesevery year - as often as a new cancer is diagnosed. With 44.000 deadly lung artery embolisms every year, thrombosis is very dangerous.
Around 30 independent risk factors are known. One of the more important risk factors seems to be the amount of intracirculatory tissue factor molecules which is brought into circulation bound to the circulating epithelial cells.
Tissue factor is always active to start the…
Circulating Tumor Cells (CTCs) Detectors Market Analysis By Application 2025 | T …
The purpose of this research report titled “Global Circulating Tumor Cells (CTCs) Detectors Market Size, Status and Forecast 2019-2025” is to enlighten the readers about the global market during the period between 2019 and 2025. Market Research Hub (MRH) has diligently compiled this study to discuss various facets of the global Circulating Tumor Cells (CTCs) Detectors market together with the various players contributing to its future development. The inclusion of…
Global Circulating Tumor Cells (CTCs) Detectors Market Insights, Forecast to 202 …
Researchmoz added Most up-to-date research on "Global Circulating Tumor Cells (CTCs) Detectors Market Insights, Forecast to 2025" to its huge collection of research reports.
This report studies the global market size of Circulating Tumor Cells (CTCs) Detectors in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Circulating Tumor Cells (CTCs) Detectors in these regions.
This research report…
Global Circulating Tumor Cells (CTCs) Detectors Market Professional Survey Repor …
To Understand the Circulating Tumor Cells Industry Status worldwide, Market Research Hub (MRH) has included the latest Forecast report titled “Global Circulating Tumor Cells Detectors Market”, to its vast database. This study offers data about the prime regions operating in the Medical Equipments sector, along with their production, consumption, revenue and market share details. Further, the intelligent report also anticipates that the market would grow at a constructive CAGR until…
maintrac® launches Immunotherapy PDL-1 blood test
Immunotherapy was one of the big topics at ASCO (American Society of Clinical Oncology) this year. Because of its potential, ASCO named it "The 2016 Clinical Cancer Advance of the Year". Immunotherapy is among today’s most promising approaches to improving the outcomes of patients.
Obtaining PD-L1 status previously required an invasive tissue biopsy. The highest quality liquid biopsy maintrac ® now makes an invasive procedure obsolete. A simple blood test, the…
